vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and SES AI Corp (SES). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $4.6M, roughly 1.0× SES AI Corp). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -373.5%, a 347.9% gap on every dollar of revenue. NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-11.1M).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
NBY vs SES — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $4.6M |
| Net Profit | $-1.2M | $-17.0M |
| Gross Margin | 65.2% | 11.3% |
| Operating Margin | -37.2% | -387.7% |
| Net Margin | -25.5% | -373.5% |
| Revenue YoY | 126.1% | — |
| Net Profit YoY | 70.5% | 50.7% |
| EPS (diluted) | — | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $3.5M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | — | $-17.0M | ||
| Q3 25 | — | $-20.9M | ||
| Q2 25 | — | $-22.7M | ||
| Q1 25 | — | $-12.4M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | — | 11.3% | ||
| Q3 25 | — | 51.1% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — |
| Q4 25 | — | -387.7% | ||
| Q3 25 | — | -262.0% | ||
| Q2 25 | — | -652.3% | ||
| Q1 25 | — | -401.7% | ||
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | — | ||
| Q1 24 | -87.1% | — |
| Q4 25 | — | -373.5% | ||
| Q3 25 | — | -293.9% | ||
| Q2 25 | — | -642.2% | ||
| Q1 25 | — | -214.6% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | — | ||
| Q1 24 | -122.2% | — |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.92 | — | ||
| Q2 24 | $-1.37 | — | ||
| Q1 24 | $-29.95 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $29.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $214.8M |
| Total Assets | $3.4M | $272.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $29.5M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $11.8M | ||
| Q1 25 | — | $56.1M | ||
| Q4 24 | $430.0K | — | ||
| Q3 24 | $776.0K | — | ||
| Q2 24 | $751.0K | — | ||
| Q1 24 | $1.8M | — |
| Q4 25 | — | $214.8M | ||
| Q3 25 | — | $228.2M | ||
| Q2 25 | — | $249.2M | ||
| Q1 25 | — | $269.9M | ||
| Q4 24 | $-129.0K | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-617.0K | — | ||
| Q1 24 | $160.0K | — |
| Q4 25 | — | $272.6M | ||
| Q3 25 | — | $288.8M | ||
| Q2 25 | — | $290.5M | ||
| Q1 25 | — | $306.0M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $3.9M | — | ||
| Q1 24 | $5.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-10.4M |
| Free Cash FlowOCF − Capex | $-1.7M | $-11.1M |
| FCF MarginFCF / Revenue | -35.4% | -243.7% |
| Capex IntensityCapex / Revenue | 0.1% | 15.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-61.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-10.4M | ||
| Q3 25 | — | $-14.3M | ||
| Q2 25 | — | $-10.8M | ||
| Q1 25 | — | $-22.8M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | $-11.1M | ||
| Q3 25 | — | $-14.7M | ||
| Q2 25 | — | $-11.6M | ||
| Q1 25 | — | $-23.7M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | -243.7% | ||
| Q3 25 | — | -206.9% | ||
| Q2 25 | — | -329.6% | ||
| Q1 25 | — | -410.0% | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | 15.6% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
SES
Segment breakdown not available.
